JAGSNPHARM — Jagsonpal Pharmaceuticals Cashflow Statement
0.000.00%
- IN₹14.65bn
- IN₹13.45bn
- IN₹2.69bn
- 80
- 21
- 59
- 56
Annual cashflow statement for Jagsonpal Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 219 | 266 | 348 | 299 | 699 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -19.5 | -29.3 | 80.4 | 66.1 | -201 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 84.4 | -183 | 26 | -29.7 | -26.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 282 | 69.1 | 467 | 352 | 553 |
| Capital Expenditures | -4.69 | -10.5 | -3.18 | -2.48 | -3.48 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -18 | -247 | -574 | -243 | -448 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -22.6 | -258 | -577 | -245 | -451 |
| Financing Cash Flow Items | -5.13 | -2.85 | -1.35 | -8.14 | -9.58 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -68.3 | -176 | -4.57 | -89.1 | -117 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 191 | -364 | -115 | 17.1 | -15.4 |